Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease

McMahan, Rachel H., Wang, Xiaoxin X., Cheng, Lin Ling, Krisko, Tibor, Smith, Maxwell, El Kasmi, Karim, Pruzanski, Mark, Adorini, Luciano +3 more·2013·Journal of Biological Chemistry
DOI 10.1074/jbc.m112.446575

Cited by (225)

Items 101–200 of 225

  1. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
    Jonathan David Roth, Sanne Skovgård Veidal, Louise K. D. Fensholdt, Kristoffer T. G. Rigbolt, Romeo Papazyan, Jens Christian Nielsen, Michael Feigh, Niels Vrang, Mark A. Young, Jacob Jelsing et al. · 2019 · Scientific Reports
  2. Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage
    Maria Reich, Caroline Klindt, Kathleen Deutschmann, Lina Spomer, Dieter Häussinger, Verena Keitel · 2017 · Digestive Diseases
  3. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
    Qinwei Yu, Zhenzhou Jiang, Luyong Zhang · 2018 · Pharmacology & Therapeutics
  4. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization
    Janne Prawitt, Sandrine Caron, Bart Staels · 2014 · Trends in Endocrinology and Metabolism
  5. TGR5 in inflammation and cardiovascular disease
    Thijs W.H. Pols · 2014 · Biochemical Society Transactions
  6. TGR5/Cathepsin E signaling regulates macrophage innate immune activation in liver ischemia and reperfusion injury
    Haoming Zhou, Shun Zhou, Yong Shi, Qi Wang, Song Wei, Ping Wang, Feng Cheng, Johan H. Auwerx, Kristina Schoonjans, Ling Lü · 2020 · American Journal of Transplantation
  7. Signaling from Intestine to the Host: How Bile Acids Regulate Intestinal and Liver Immunity
    Michele Biagioli, Adriana Carino · 2019 · Handbook of experimental pharmacology
  8. Exploring the binding properties of agonists interacting with human TGR5 using structural modeling, molecular docking and dynamics simulations
    Thangaraj Sindhu, P. Srinivasan · 2015 · RSC Advances
  9. Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
    Meng-Jiao Zhou, Danfeng Wang, Xiang Li, Ying Cao, Cheng-Xue Yi, Dickson Kofi Wiredu Ocansey, Yulin Zhou, Fei Mao · 2022 · Frontiers in Pharmacology
  10. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting
    Arjuna Singanayagam, Evangelos Triantafyllou · 2021 · Frontiers in Immunology
  11. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
    Jana Hundertmark, Oliver Krenkel, Frank Tacke · 2018 · Frontiers in Immunology
  12. Gut Microbiota and Its Metabolite Deoxycholic Acid Contribute to Sucralose Consumption-Induced Nonalcoholic Fatty Liver Disease
    Zunji Shi, Gui Chen, Zheng Cao, Fang Wu, Hehua Lei, Chuan Chen, Yuchen Song, Caixiang Liu, Jinquan Li, Jinlin Zhou et al. · 2021 · Journal of Agricultural and Food Chemistry
  13. The Gut–Liver Axis in Chronic Liver Disease: A Macrophage Perspective
    Kevin De Muynck, Bart Vanderborght, Hans Van Vlierberghe, Lindsey Devisscher · 2021 · Cells
  14. Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4−/− Mice
    M. Cariello, Claudia Peres, R. Zerlotin, Emanuele Porru, C. Sabbà, A. Roda, A. Moschetta · 2017 · Scientific Reports
  15. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
    Anfuso, Beatrice, Tiribelli, Claudio, Adorini, Luciano, Rosso, Natalia · 2020 · Scientific Reports
  16. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease
    Alessandro Federico · 2014 · World Journal of Gastroenterology
  17. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
    Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji · 2014 · World Journal of Gastroenterology
  18. NOD1 in the interplay between microbiota and gastrointestinal immune adaptations
    Victoria Fernández-García, Silvia González-Ramos, Paloma Martín‐Sanz, Francisco Garcia del Portillo, José Moisés Laparra, Lisardo Boscá · 2021 · Pharmacological Research
  19. Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition–associated cholestasis in mice
    Karim Christian El Kasmi, Swati Ghosh, Aimee L. Anderson, Michael W. Devereaux, Natarajan Balasubramaniyan, Angelo D’Alessandro, David J. Orlicky, Frederick J. Suchy, Colin T. Shearn, Ronald J. Sokol · 2021 · Hepatology
  20. Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
    Slavica Lazarević, Maja Đanić, Svetlana Goločorbin-Kon, Hani Al‐Salami, Momir Mikov · 2019 · Pharmacological Research
  21. Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis
    Yingmei Tang, Jia-Ping Wang, WEI-MIN BAO, Jinhui Yang, Linkun Ma, Jing Yang, HUI CHEN, Ying Xu, Lihong Yang, Wen Li et al. · 2015 · International Journal of Molecular Medicine
  22. Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
    Benoit Smeuninx, Ebru Boslem, Mark Anthony Febbraio · 2020 · Cancers
  23. Liver Inflammation Relates to Decreased Canalicular Bile Transporter Expression in Pediatric Onset Intestinal Failure
    A. Mutanen, J. Lohi, P. Heikkilä, H. Jalanko, M. Pakarinen · 2017 · Annals of Surgery
  24. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets
    Zilu Cheng, Yixiong Chen, Bernd Schnabl, Huikuan Chu, Ling Yang · 2023 · Journal of Advanced Research
  25. Beneficial effects of bile acid receptor agonists in pulmonary disease models
    Paolo Comeglio, Annamaria Morelli, Luciano Adorini, Mario Maggi, Linda Vignozzi · 2017 · Expert Opinion on Investigational Drugs
  26. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances
    Vania Cruz-Ramón, Paulina Chinchilla-López, Oscar Ramírez-Pérez, Nahúm Méndez‐Sánchez · 2017 · Annals of Hepatology
  27. Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
    Meilin Wei, Wei Tu, Genhua Huang · 2024 · Frontiers in Microbiology
  28. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease
    Brett M. McGettigan, Rachel H. McMahan, Yuhuan Luo, Xiaoxin X. Wang, David J. Orlicky, Cara E. Porsche, Moshe Levi, Hugo R. Rosen · 2016 · Journal of Biological Chemistry
  29. Farnesoid X Receptor Activation Protects Liver From Ischemia/Reperfusion Injury by Up‐Regulating Small Heterodimer Partner in Kupffer Cells
    Dan Jin, Tian-Fei Lu, Ming Ni, Han Wang, Jiang Zhang, C. Zhong, Chuan Shen, Jun-Feng Hao, R. Busuttil, J. Kupiec-Weglinski et al. · 2020 · Hepatology Communications
  30. Genetics in PSC: What Do the “Risk Genes” Teach Us?
    Trine Folseraas, Evaggelia Liaskou, Carl A. Anderson, Tom H. Karlsen · 2014 · Clinical Reviews in Allergy & Immunology
  31. HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels
    Changxi Chen, Zhongwei Zhu, Yushan Mao, Yimin Xu, Juan Du, Xiaoping Tang, Hongbao Cao · 2020 · Bioscience Reports
  32. Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma
    Hélène Gilgenkrantz, Valérie Paradis, Sophie Lotersztajn · 2023 · Hepatology
  33. Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota
    Tianqi Cai, Xinhua Song, Xiaoxue Xu, Ling Dong, Shufei Liang, Meiling Xin, Yuhong Huang, Linghui Zhu, Tianxing Li, Xueke Wang et al. · 2024 · Frontiers in Cellular and Infection Microbiology
  34. Update on primary sclerosing cholangitis genetics
    Eva Kristine Klemsdal Henriksen, Espen Melum, Tom H. Karlsen · 2014 · Current Opinion in Gastroenterology
  35. NASH: A glance at the landscape of pharmacological treatment.
    Lucia Brodosi, Francesca Marchignoli, Maria Letizia Petroni, Giulio Marchesini · 2016 · PubMed
  36. The diverse roles of macrophages in metabolic inflammation and its resolution
    Aleepta Guha Ray, Oluwatomilayo Odum, Destini Wiseman, Ada Weinstock · 2023 · Frontiers in Cell and Developmental Biology
  37. Macrophages as Key Players during Adipose Tissue–Liver Crosstalk in Nonalcoholic Fatty Liver Disease
    Hannelie Korf, Markus Boesch, Lore Meelberghs, Van der Merwe · 2019 · Seminars in Liver Disease
  38. Polyphenols improve non‐alcoholic fatty liver disease via gut microbiota: A comprehensive review
    Kimia Mohammadhasani, Mohammad Vahedi Fard, Ali Mottaghi Moghaddam Shahri, Zahra Khorasanchi · 2024 · Food Science & Nutrition
  39. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
    Nan Yao, Yixue Yang, Xiaotong Li, Yuxiang Wang, Ruirui Guo, Xuhan Wang, Jing Li, Zechun Xie, Bo Li, Weiwei Cui · 2022 · Frontiers in Nutrition
  40. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
    Samarth Siddharth Patel, Mohammad Shadab Siddiqui · 2018 · Drugs
  41. Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease
    Justine Gillard, Isabelle Anne Leclercq · 2023 · Clinical Science
  42. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis
    Fan Lian, YU WANG, Youjun Xiao, Xiwen Wu, Hanshi Xu, Liuqin Liang, Xiuyan Yang · 2015 · Molecular Medicine Reports
  43. Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
    Benedikt Simbrunner, Rafael Paternostro, Thomas Reiberger, Michael Trauner · 2025 · Hepatology
  44. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis
    Waleska Cláudia Dornas, Vincent Lagente · 2019 · Pharmacological Research
  45. The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
    Ronca, Vincenzo, Davies, Scott P., Oo, Ye Htun, Lleo, Ana · 2025 · Hepatology
  46. Monocyte regulation by gut microbial signals
    Panayota Kolypetri, Howard L. Weiner · 2023 · Trends in Microbiology
  47. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
    Ricardo Amorim, Pedro Soares, Daniel Chavarria, Sofia Benfeito, Fernando Cagide, José Teixeira, Paulo Jorge Oliveira, Fernanda Borges · 2024 · European Journal of Medicinal Chemistry
  48. A novel murine model of multi-day moderate ethanol exposure reveals increased intestinal dysfunction and liver inflammation with age
    Rachel H. McMahan, Kevin M. Najarro, Juliet E. Mullen, Madison T. Paul, David J. Orlicky, Holly J. Hulsebus, Elizabeth J. Kovacs · 2021 · Immunity & Ageing
  49. Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism
    Justine Gillard, Corinne Picalausa, Christoph Ullmer, Luciano Adorini, Bart Staels, Anne Tailleux, Isabelle Anne Leclercq · 2022 · Nutrients
  50. Influence of the gut microbiota on endometriosis: Potential role of chenodeoxycholic acid and its derivatives
    Yangshuo Li, Kaili Wang, Jie Ding, Shuai Sun, Zhexin Ni, Chaoqin Yu · 2022 · Frontiers in Pharmacology
  51. Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy
    Miljana Nenkov, Yihui H. Shi, Yunxia Ma, Nikolaus Gaßler, Yuan Chen · 2023 · International Journal of Molecular Sciences
  52. Role of Bile Acid Receptors in the Development and Function of Diabetic Nephropathy
    Yuanyuan Fang, Minjing Qin, Qitong Zheng, Kuilong Wang, Xin Han, Qiao Yang, Xia’nan Sang, Gang Cao · 2024 · Kidney International Reports
  53. TGR5 ligands as potential therapeutics in inflammatory diseases
    Thijs W.H. Pols, Hannah M. Eggink, Maarten R. Soeters · 2014 · International Journal of Interferon Cytokine and Mediator Research
  54. Bile acid‐activated receptors in innate and adaptive immunity: targeted drugs and biological agents
    Kenneth C. P. Cheung, Jiao Ma, Rodrigo Azevedo Loiola, Xingxuan Chen, Wei Ping Jia · 2023 · European Journal of Immunology
  55. Roles of Bile Acid-Activated Receptors in Monocytes-Macrophages and Dendritic Cells
    Huilin Jia, Xia He, Tengfei Jiang, Fanzhi Kong · 2025 · Cells
  56. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
    Sachiho Miyata, Yuji Kawashima, Miku Sakai, Masaya Matsubayashi, Keisuke Motoki, Yui Miyajima, Yousuke Watanabe, Noriko Chikamatsu, Tetsuya Taniguchi, Ryukou Tokuyama · 2021 · Scientific Reports
  57. Bile Acid Dysregulation Is Intrinsically Related to Cachexia in Tumor-Bearing Mice
    Morgane M. Thibaut, Justine Gillard, Adeline Dolly, Martin Roumain, Isabelle Anne Leclercq, Nathalie M. Delzenne, Giulio G. Muccioli, Laure B. Bindels · 2021 · Cancers
  58. Polygoni Multiflori Radix Praeparata Ethanol Extract Exerts a Protective Effect Against High-Fat Diet Induced Non-Alcoholic Fatty Liver Disease in Mice by Remodeling Intestinal Microbial Structure and Maintaining Metabolic Homeostasis of Bile Acids
    Xuyang Dai, Linfeng He, Naihua Hu, Chaocheng Guo, Mengting Zhou, Xingtao Zhao, Cheng Wang, Lihong Gong, Cheng Ma, Xinyan Xue et al. · 2021 · Frontiers in Pharmacology
  59. Changes in gut microbiome correlate with intestinal barrier dysfunction and inflammation following a 3-day ethanol exposure in aged mice
    Rachel H. McMahan, Holly J. Hulsebus, Kevin M. Najarro, Lauren E. Giesy, Daniel N. Frank, Elizabeth J. Kovacs · 2022 · Alcohol
  60. Evolving therapies for non-alcoholic steatohepatitis
    Herbert Tilg, Alexander Rupert Moschen · 2014 · Expert Opinion on Drug Discovery
  61. Dietary and metabolic modulators of hepatic immunity
    Antonella Carambia, Johannes Herkel · 2017 · Seminars in Immunopathology
  62. Conjugated Lithocholic Acid Activates Hepatic TGR5 to Promote Lipotoxicity and MASLD‐MASH Transition by Disrupting Carnitine Biosynthesis
    Senlin Lian, Meixi Lu, Luo Jiajing, Bin Zhang, Yi Fang, Xuran Wang, Ming‐Hua Zheng, Yan Ni, Guifang Xu, Yonglin Yang et al. · 2025 · Advanced Science
  63. Bile acid receptors link nutrient sensing to metabolic regulation
    Jibiao Li, Tiangang Li · 2017 · Liver Research
  64. Research progress regarding the effect and mechanism of dietary phenolic acids for improving nonalcoholic fatty liver disease via gut microbiota
    Lin Ji, Huan Deng, Huimin Xue, Jiting Wang, Kexin Hong, Yunxiao Gao, Xiping Kang, Guanghe Fan, Weidong Huang, Jicheng Zhan et al. · 2023 · Comprehensive Reviews in Food Science and Food Safety
  65. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
    Maria Nicoline Baandrup Kristiansen, Sanne Skovgård Veidal, Christina Christoffersen, Michael Feigh, Niels Vrang, Jonathan David Roth, Mary Erickson, Luciano Adorini, Jacob Jelsing · 2019 · BMC Gastroenterology
  66. Bile Acid Network and Vascular Calcification-Associated Diseases: Unraveling the Intricate Connections and Therapeutic Potential
    Cui Wang, Qing Ma, Xijie Yu · 2023 · Clinical Interventions in Aging
  67. Bile Acid-Induced Liver Injury in Cholestasis
    Tiangang Li, John Y.L. Chiang · 2017 · Springer eBooks
  68. The discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists
    Andreas Luxenburger, Lawrence D. Harris, Elizabeth M. Ure, Wanting Jiao, Anthony D. Woolhouse, Scott A. Cameron, Alex Weymouth‐Wilson, Richard H. Furneaux, Janet L. Pitman, Simon F.R. Hinkley · 2023 · European Journal of Medicinal Chemistry
  69. Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies
    Jacob Beiriger, Kashyap Chauhan, Adnan Khan, Taha Shahzad, Natalia Salinas Parra, Peter G. Y. Zhang, Sarah Chen, Tuan Anh Nguyen, Brian M. Yan, John Bruckbauer et al. · 2023 · Livers
  70. Nerve growth factor induced farnesoid X receptor upregulation modulates autophagy flux and protects hepatocytes in cholestatic livers
    Ming‐Shian Tsai, Hui-Ming Lee, Shih-Che Huang, Cheuk‐Kwan Sun, Ting-Chia Chiu, Po‐Han Chen, Yu‐Chun Lin, Tzu‐Min Hung, Po‐Huang Lee, Y. H. Kao · 2020 · Archives of Biochemistry and Biophysics
  71. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Mikkel Breinholt Kjær, Jacob George, Konstantin Kazankov, Henning Grønbæk · 2020 · Expert Review of Gastroenterology & Hepatology
  72. INT-767—A Dual Farnesoid-X Receptor (FXR) and Takeda G Protein-Coupled Receptor-5 (TGR5) Agonist Improves Survival in Rats and Attenuates Intestinal Ischemia Reperfusion Injury
    Emilio Canovai, Ricard Farré, Alison Accarie, Mara Lauriola, Gert D. Hertogh, Tim Vanuytsel, Jacques Pirenne, Laurens Joseph Ceulemans · 2023 · International Journal of Molecular Sciences
  73. Novel Targets in the Immune Microenvironment of the Hepatic Sinusoids for Treating Liver Diseases
    Daniel A. Patten, Emma L. Shepherd, Chris J. Weston, Shishir Shetty · 2019 · Seminars in Liver Disease
  74. Immunoregulatory Functions of Nuclear Receptors: Mechanisms and Therapeutic Implications
    Linjie Zhao, Ryan C. Gimple, Zhengnan Yang, Yuquan Wei, Jan-Ακε Gustafsson, Shengtao Zhou · 2019 · Trends in Endocrinology and Metabolism
  75. Lithocholic Acid Species: Metabolism, Signaling Pathways, and Clinical Significance in Enterohepatic Diseases
    Lianggui Leng, Guangzeng Zhou, Ana Liu, Huiying Wang, Yan Ni · 2025 · International Journal of Molecular Sciences
  76. Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders
    Sosmitha Girisa, B. Aswani, M. Manickasamy, Mangala Hegde, M. Alqahtani, Mohamed Abbas, Gautam Sethi, A. Kunnumakkara · 2025 · Expert opinion on therapeutic targets
  77. Gut Microbiota–Immune System Crosstalk
    Francesca Fava · 2014 · Elsevier eBooks
  78. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters
    Ying Wang, Yao Zhu, Junxing Niu, Qiangqiang Deng, Shimeng Guo, Haowen Jiang, Zhaoliang Peng, Yaru Xue, Huige Peng, Lijiang Xuan et al. · 2020 · Toxicology and Applied Pharmacology
  79. Development of 3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-sulfate sodium salt (INT-767): Process optimization, synthesis and characterization of metabolites
    Bruno Cerra, Francesco Venturoni, Maria Souma, Giada Ceccarelli, Anna Maria Lozza, Daniela Passeri, Francesca Franco, Ian R. Baxendale, Roberto Pellicciari, Antonio Macchiarulo et al. · 2022 · European Journal of Medicinal Chemistry
  80. Dynamics of Liver Macrophage Subsets in a Novel Mouse Model of Non-Alcoholic Steatohepatitis Using C57BL/6 Mice
    Nana Makiuchi, Shun Takano, Yuki Tada, Kaichi Kasai, Naoya Igarashi, Koudai Kani, Miyuna Kato, Kana Goto, Yudai Matsuura, Mayuko Ichimura‐Shimizu et al. · 2023 · Biomedicines
  81. Impacts of liver macrophages, gut microbiota, and bile acid metabolism on the differences in iHFC diet-induced MASH progression between TSNO and TSOD mice
    Naoya Igarashi, Kaichi Kasai, Yuki Tada, Koudai Kani, Miyuna Kato, Shun Takano, Kana Goto, Yudai Matsuura, Mayuko Ichimura‐Shimizu, Shiro Watanabe et al. · 2024 · Inflammation Research
  82. Maltitol Prevents the Progression of Fatty Liver Degeneration in Mice Fed High-Fat Diets
    Hayato Urushima, Yasuaki Sanada, Miki Sakaue, Yūji Matsuzawa, Toshinori Ito, Kazuhisa Maeda · 2015 · Journal of Medicinal Food
  83. Myeloid Cells and Chronic Liver Disease: a Comprehensive Review
    Min Lian, Carlo Francesco Selmi, Merrill Eric Gershwin, Xiong Ma · 2018 · Clinical Reviews in Allergy & Immunology
  84. Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
    Roman Vyacheslavovich Maslennikov, Yu. V. Evsyutina · 2018 · Russian Journal of Gastroenterology Hepatology Coloproctology
  85. Bile Acids as Signaling Molecules
    Thierry Claudel, Michael A Trauner · 2020 · Liver
  86. The Role of Hypoxia-Induced Mitogenic Factor in Organ-Specific Inflammation in the Lung and Liver: Key Concepts and Gaps in Knowledge Regarding Molecular Mechanisms of Acute or Immune-Mediated Liver Injury
    Sananda Pai, Dolores B. Njoku · 2021 · International Journal of Molecular Sciences
  87. An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance
    Rakesh Sahu, Rakhi Mishra, Chandana Majee · 2020 · Expert Review of Gastroenterology & Hepatology
  88. Bile Acids and TGR5 (Gpbar1) Signaling
    Verena Keitel, Christoph G. W. Gertzen, Sven Schäfer, Caroline Klindt, Christina Wöhler, Kathleen Deutschmann, Maria Reich, Holger Gohlke, Dieter Häussinger · 2020 · Springer eBooks
  89. Perspective strategies for non-alcoholic fatty liver disease therapy: from trial to practice
    Игорь Геннадьевич Бакулин, L. N. Belousova, Nazarenko Li, A. G. Sushilova · 2020 · Экспериментальная и клиническая гастроэнтерология
  90. The Role of Bile Acid Receptors in Chronic Inflammatory Diseases
    Robin Park, Jong Dae Ji · 2017 · Journal of Rheumatic Diseases
  91. Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
    Ye Eun Cho, Yong Seong Kwon, Seonghwan Hwang · 2022 · Liver Research
  92. EDP ‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects
    Christine Marotta, Alaa Mohammad Ahmad, Ed Luo, Jart A. F. Oosterhaven, Sjoerd van Marle, Nathalie Adda · 2022 · Clinical and Translational Science
  93. The macrophage opera: from metabolic prolog to oncogenic crescendo in metabolic dysfunction-associated steatotic liver disease
    Gaoling Huang, Dan Li · 2026 · Frontiers in Medicine
  94. Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease
    Alaa Mohammad Ahmad, Kristin Sanderson, Daniel Dickerson, Nathalie Adda · 2021 · International Journal of Gastroenterology
  95. Identification and validation of immune related core transcription factors GTF2I in NAFLD
    Minbo Zhang, Yu Zhang, Xiaoxiao Jiao, Lin-Ying Lai, Yi-Ting Qian, Bo Sun, Wen-Zhuo Yang · 2022 · PeerJ
  96. Phenotype transition of monocytes and liver injury
    Dexi Zhou, Zhen Lin, Lingna Kong, Jun Li · 2013 · Liver International
  97. TGR5 (GPBAR1) in the Liver
    Verena Keitel, Christoph G. W. Gertzen, Lina Spomer, Holger Gohlke, Dieter Häussinger · 2020
  98. Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
    Feifei Li, Qiujing Chen, Yang Dai, Lin Lu · 2025 · iScience
  99. Bile acids and their receptors
    Thierry Claudel, Michael A Trauner · 2015
  100. STUDY OF FXR IN PRIMARY HUMAN HEPATOCYTES AND FXR REGULATED BA HOMEOSTASIS IN PARENTERAL NUTRITION ASSOCIATED LIVER DISEASES
    Le Zhan · 2014 · KU ScholarWorks (The University of Kansas)